Capital Research Global Investors Acquires 721,154 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Capital Research Global Investors boosted its stake in Cellebrite DI by 42.3%, acquiring 721,154 shares to own 2,425,736 shares (about 1.01% of the company) valued at approximately $44.95 million per the latest 13F filing.
• Cellebrite reported quarterly EPS of $0.14 (in line with estimates) and revenue of $128.82 million, up 28.8% year‑over‑year, while the stock trades near $14.53 with a market cap of $3.62 billion and a P/E of 46.87.
• Analyst sentiment is mixed—four Buy ratings and one Sell yield an average "Moderate Buy" and a consensus price target of $22.50—and institutional investors hold about 45.88% of the shares.

Capital Research Global Investors raised its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 42.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,425,736 shares of the company's stock after acquiring an additional 721,154 shares during the period. Capital Research Global Investors owned about 1.01% of Cellebrite DI worth $44,949,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Financial Management Professionals Inc. acquired a new position in shares of Cellebrite DI in the 3rd quarter valued at approximately $28,000. CWM LLC raised its holdings in Cellebrite DI by 85.7% during the 3rd quarter. CWM LLC now owns 1,560 shares of the company's stock worth $29,000 after buying an additional 720 shares during the period. PNC Financial Services Group Inc. raised its holdings in Cellebrite DI by 1,998.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company's stock worth $34,000 after buying an additional 1,998 shares during the period. Toth Financial Advisory Corp bought a new position in Cellebrite DI in the third quarter valued at approximately $38,000. Finally, Pacer Advisors Inc. boosted its holdings in shares of Cellebrite DI by 523.4% in the third quarter. Pacer Advisors Inc. now owns 2,743 shares of the company's stock valued at $51,000 after buying an additional 2,303 shares during the period. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Trading Up 0.3%

Cellebrite DI stock opened at $14.53 on Friday. Cellebrite DI Ltd. has a 1-year low of $11.76 and a 1-year high of $20.86. The company has a fifty day simple moving average of $15.34 and a 200 day simple moving average of $16.91. The company has a market cap of $3.62 billion, a P/E ratio of 46.87, a price-to-earnings-growth ratio of 2.22 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 EPS for the quarter, hitting the consensus estimate of $0.14. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The firm had revenue of $128.82 million for the quarter, compared to analysts' expectations of $126.07 million. During the same period in the previous year, the firm posted $0.10 EPS. The company's revenue for the quarter was up 28.8% on a year-over-year basis. On average, equities research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Cellebrite DI from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. Bank of America upped their target price on shares of Cellebrite DI from $24.00 to $25.00 and gave the stock a "buy" rating in a research note on Thursday, November 13th. Lake Street Capital increased their target price on Cellebrite DI from $22.00 to $23.00 and gave the stock a "buy" rating in a report on Thursday, November 13th. JPMorgan Chase & Co. lifted their price target on Cellebrite DI from $23.00 to $24.00 and gave the company an "overweight" rating in a research note on Thursday, November 13th. Finally, Needham & Company LLC cut their price target on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 12th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $22.50.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.